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Abstract
Background: The aim of this study is to determine to what extent barriers perceived by general
practitioners (GPs) for prescribing angiotensin-converting enzyme inhibitors (ACE-I) in chronic
heart failure (CHF) patients are related to underuse and underdosing of these drugs in actual
practice.
Methods: Barriers were assessed with a semi-structured questionnaire. Prescribing data were
extracted from GPs' computerised medical records for a random sample of their CHF patients.
Relations between barriers and prescribing behaviour were assessed by means of Spearman rank
correlation and multivariate regression modelling.
Results: GPs prescribed ACE-I to 45% of their patients and had previously initiated such treatment
in an additional 3.5%, in an average standardised dose of 13.5 mg. They perceived a median of  four
barriers in prescribing ACE-I or optimising ACE-I dose. Many GPs found it difficult to change
treatment initiated by a cardiologist. Furthermore, initiating ACE-I in patients already using a
diuretic or stable on their current medication was perceived as barrier. Titrating the ACE-I dose
was seen as difficult by more than half of the GPs. No significant relationships could be found
between the barriers perceived and actual ACE-I prescribing. Regarding ACE-I dosing, the few GPs
who did not agree that the ACE-I should be as high as possible prescribed higher ACE-I doses.
Conclusion:  Variation between GPs in prescribing ACE-I for CHF cannot be explained by
differences in the barriers they perceive. Tailor-made interventions targeting only those doctors
that perceive a specific barrier will therefore not be an efficient approach to improve quality of care.
Background
Despite several landmark studies showing that appropri-
ate treatment of chronic heart failure (CHF) can improve
morbidity and mortality, management in general practice
is still not optimal. Persisting major problems are under-
use and underdosing of angiotensin-converting enzyme
inhibitors (ACE-I) [1].
General practitioners (GPs) perceive problems that may
explain why they do not treat their CHF patients
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optimally [2-5]. These problems can be classified as inter-
nal or external barriers. Internal barriers include lack of
knowledge, e.g. not knowing the target dose of ACE-I or
lack of awareness of new recommendations, as well as cer-
tain attitudes, such as lack of confidence, doubts about
benefits for very old patients, fear for adverse effects or
reluctance to change the treatment when a patient is sta-
ble. External barriers may be related to organisational fac-
tors, including difficulties at the primary-secondary care
interface.
It is often suggested that intervention programs for
improving performance need to be targeted at perceived
barriers [6,7]. However, several tailored interventions
addressing identified barriers did not change professional
performance [8,9]. It might be that not all barriers identi-
fied are as relevant for not achieving optimal manage-
ment. In the case of CHF management, lack of knowledge
appears not to be very pertinent [10,11]. Furthermore,
doctors may not be fully aware of the factors influencing
their performance, because self-insight in treatment deci-
sions is limited [12]. To our knowledge, no study has tried
to assess the relationship between the GPs' self-reported
problems with specific treatment recommendations and
their actual prescribing for heart failure. Better under-
standing of this relation may help to indicate areas in
which an intervention could be most beneficial.
The aim of our study is to determine to what extent barri-
ers that GPs perceive for prescribing ACE-I in CHF patients
are related to their actual prescribing.
Methods
Study population and setting
This study was part of the baseline of a larger study con-
ducted from September 2001 to May 2002 in the north of
the Netherlands, evaluating two audit programs for peer
review groups focussing on the treatment of CHF and
treatment of hypertension in diabetic patients. In the
Netherlands, nearly all GPs participate in such peer review
groups. Of the 27 peer review groups in our region, 21
participated in the larger study. A total of ten peer review
groups consisting of 97 GPs were randomised to the
chronic heart failure program, and therefore eligible for
this study (Figure 1).
Prescribing data were extracted from the GPs' computer-
ised medical records. In most practices, GPs have personal
lists of patients. Data were collected for a random sample
of 10 CHF patients per practice using computer generated
random numbers. The estimated prevalence of CHF lies
between 15–30 patients for an average patient list in the
Netherlands of 2400 patients per GP [13]. All patients
with a diagnostic code for CHF or the text 'heart failure',
'cardiac asthma', 'cardiac decompensation' or 'left ven-
tricular dysfunction' in their medical records were selected
from the medical records as possible CHF patients. GPs
General practitioners (GPs) and patients in study Figure 1




 36 GPs did not attend meeting where
   questionnaire was distributed
 3 GPs did not complete questionnaire
All 97 GPs from
 10 peer groups
 Prescribing data could not be
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were asked to verify the diagnosis. Because of the larger
study, CHF patients with a co-morbidity of diabetes type
2 were excluded.
Perceived barriers
GPs present at the audit meeting of their peer review
group were asked to complete a semi-structured question-
naire on their perceived problems with the recommended
treatment for CHF. This questionnaire was developed
with statements of possible internal and external barriers
towards prescribing ACE-I in patients with heart failure as
identified from the literature [2-5]. The literature-based
barriers included three general beliefs supporting the rec-
ommended treatment. Disagreement with these was con-
sidered an internal barrier. Six specific beliefs and
attitudes opposing the general recommendations were
presented, each also representing a possible internal bar-
rier. Furthermore, two external barriers were included
which were related to the sharing of responsibilities
between primary and secondary care (Table 1). An open-
ended question was added to identify any other barriers
the GPs perceived with implementing evidence-based rec-
ommendations for CHF treatment. These self-reported
barriers were categorised in nine themes by the first two
authors. A content analysis based on an inductive
approach was conducted. First, the two authors independ-
ently identified the main issues described by the GPs. This
resulted in thirteen issues that after comparison and dis-
cussion were reduced to nine separate themes. Next, both
researchers independently classified all reported barriers
to one of the nine themes. Discrepancies were discussed
until agreement was reached.
Actual treatment
Actual treatment data were extracted from computerised
medical records by third and fourth year medical students
trained to copy all relevant medical and prescription data
on structured forms. When two GPs shared their list of
patients, prescribing decisions were assigned to both GPs
reflecting their joint prescribing policy. Data collected for
the patients included age, gender, date of CHF onset, spe-
cialist referrals and current medication. For each GP, the
percentage of patients currently or previously treated with
an ACE-I was calculated as outcome variable, as well as
Table 1: Perceived internal and external barriers for prescribing ACE-I for CHF, divided in literature-based and self-reported barriers 
(N = number of GPs reporting barrier)
Literature-based barriers N Self-reported barriers N
Internal Do not agree with: I believe that the standard therapy for new 
CHF patients should be an ACE-I, irrespective of the severity of 
the disease
1
I believe that the standard therapy for known CHF patients 
should be an ACE-I, irrespective of the severity of the disease
2
I believe that ACE-I should be prescribed in as high a dose as 
possible for CHF patients
2
Agree with: I believe one should be reserved in prescribing ACE-
I to CHF patients, because of the risk of renal insufficiency
11 Starting, checking, and titrating ACE-I dose is difficult 3
I believe one should be reserved in prescribing ACE-I to CHF 
patients, because of the risk of hypotension
12 Fears about adverse effects of ACE-I 8
I find initiating ACE-I difficult in CHF patients already using a 
diuretic
18
I find it difficult to frequently titrate the ACE-I dose in CHF 
patients
25
I believe that CHF patients who are stable on their current 
medication, should not be put on an ACE-I
18 Not wanting to change treatment when patients are stable 4
I believe it is not useful to prescribe ACE-I to very old CHF 
patients
10 Doubts about usefulness of ACE-I, especially in elderly 
patients
3
Difficulties with treating complex cases (comorbidity/
polyfarmacy)
3
External Problems with patient compliance or motivation 5
I believe that a cardiologist should initiate ACE-I therapy in CHF 
patients
3 Problems in interacting with specialist care 9
I find it hard to change treatment initiated by a cardiologist 33
Time constraints 1
Difficulties with screening for undertreated heart failure 
patients
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the average dosing of the ACE-I currently prescribed. The
ACE-I dosages were first converted to standardised dos-
ages according to target daily doses for heart failure as rec-
ommended in the Dutch desk reference book [14]. This
method of standardisation, which has been used before,
uses 20 mg of enalapril as reference dose [15]. Based on
the conversion, enalapril 20 mg equivalents are captopril
150 mg, ramipril 10 mg, quinapril 20 mg, lisinopril 20
mg, fosinopril 40 mg, and perindopril 4 mg. This conver-
sion is an alternative for the more commonly used
defined daily dosage (DDD) method, which can not be
applied in this case since the DDDs for ACE-I are based on
their use for hypertension.
Data analysis
Prescribing of ACE-I was aggregated at GP level to assess
the relationship between the perceived barriers and over-
all prescribing behaviour. We checked at patient level with
chi-square tests whether ACE-I prescribing differed signif-
icantly for different age-groups, gender and comorbidity
of the patients. Differences between participating and
non-participating GPs were tested with t-tests or chi-
square tests.
The number of different barriers perceived was related to
the percentage of patients currently or previously being
prescribed an ACE-I and to the average standardised ACE-
I dose prescribed with Spearman rank correlations (ρ ).
This non-parametric statistic was used since the number
of barriers perceived did not have a normal distribution.
Two sub-analyses were conducted to assess whether rela-
tions differed for internal versus external barriers, and for
literature-based versus self-reported barriers. Next, we
looked at the relationship between individual barriers and
actual ACE-I prescribing. The data were first explored uni-
variate by means of Mann-Whitney tests. A stepwise mul-
tivariate linear regression model was used to assess the
relevance of all 11 literature-based and five self-reported
barriers for explaining differences in ACE-I prescribing
aggregated at GP level. The other self-reported barriers
overlapped with literature based barriers and were
excluded from this regression analysis. Finally, the com-
plete data analysis was repeated for ACE-I prescribing for
a subgroup of patients who had not been referred to a car-
diologist in the year prior to data collection. This was
decided when it became clear that a substantial number of
patients had been referred in the last year, and one might
expect that treatment initiated by the specialist confounds
the analysis [16].
Results
Fifty-eight GPs completed the questionnaire, and pre-
scribing behaviour was measured for 43 of them, resulting
in an overall response rate of 44% (Figure 1). The GPs par-
ticipating in this study were mainly male (88%), and on
average 47 years old (SD 6.9), which was not significantly
different from the non-responding GPs (83% male, 48
years). They had an average practice size of 2485 patients
(SD 244) and 60% were single-handed. In comparison,
the average Dutch practice size in 2001/2002 was 2430
patients, and 40% of the GPs was single-handed. In thir-
teen practices, less than ten verified CHF patients could be
identified. In another three practices, two GPs shared the
responsibility for the same patients. Prescribing behav-
iour was therefore assessed for 339 patients. In 11% of the
cases, the diagnosis was confirmed by a recorded
echocardiography. The GPs prescribed an ACE-I to an
average of 44.9% (SD 15.9) of their CHF patients in an
average standardised dose of 13.5 mg (SD 6.6). Another
3.5% of the patients had been using an ACE-I prior to the
study period, including 7 patients that had stopped using
ACE-I because of various side effects and 5 who had
stopped without a documented reason. Including these
patients, the GPs prescribed or had previously prescribed
an ACE-I to 48.6% of their patients (SD 17.9). This was
not significantly different from GPs who did not attend
the meeting (47.3%). ACE-I prescribing was significantly
lower for patients over 85 years of age (32.8%). ACE-I pre-
scribing did not significantly differ according to the
patients' gender or comorbidity. Angiotensin-II-antago-
nists were prescribed to 6% of the patients.
All but two GPs considered ACE-I as standard therapy for
all CHF patients, and most GPs agreed that ACE-I should
be dosed as high as possible (Table 1). The median
number of barriers perceived in prescribing ACE-I or opti-
mising ACE-I dosage was four. All 43 GPs perceived at
least one barrier; 41 GPs perceived at least one internal
barrier, and 37 GPs perceived at least one external barrier
(Table 2).
Relationship between number of barriers and ACE-I 
prescribing
No relationship appeared to exist between the number of
barriers and the ACE-I prescribing at GP level (Table 2).
No significant correlations were found between the total
number of barriers perceived by the GPs and the percent-
age of patients receiving an ACE-I (ρ  = .02) or the average
ACE-I dose prescribed (ρ  = -.08). Also, no significant cor-
relations were found with the number of internal or exter-
nal barriers, nor with the number of literature-based or
self-reported barriers.
Literature-based barriers
With regard to initiating an ACE-I, a substantial number
of GPs (42%) reported that they were afraid of endanger-
ing a stable situation and reluctant to start an ACE-I when
a patient already received a diuretic (Table 1). The most
important barrier regarding the ACE-I dosing was the dif-
ficulty perceived with titrating this dose. A majority of theBMC Family Practice 2005, 6:19 http://www.biomedcentral.com/1471-2296/6/19
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GPs (77%) found it hard to change treatment initiated by
a cardiologist. The univariate analysis showed no signifi-
cant relationships between the individual barriers and
ACE-I prescribing, and the scatter plots also revealed no
patterns. Even GPs who believed it is not useful to pre-
scribe ACE-I to very old CHF patients did not have less
patients of 85 years or older on these drugs (univariate
correlation ρ  = .19, p = 0.3). In the stepwise linear regres-
sion model using forward selection, none of the 11 litera-
ture-based barriers was found to be related to the
percentage of patients currently of previously receiving an
ACE-I. The model as a whole did not significantly explain
the prescribing differences at GP level (R-square = 0.17).
Also, a model including only the five internal barriers
directly related to ACE-I prescribing, i.e. fear of renal
insufficience, fear of hypotension, difficulty in initiating
ACE-I in patients on diuretics, not wanting to start ACE-I
in stable patients, not wanting to prescribe ACE-I to very
old patients, could not predict ACE-I prescribing (R-
square = 0.10).
Surprisingly, the two GPs who did not agree that the ACE-
I dose should be as high as possible, prescribed higher
doses than GPs who did agree with this recommendation.
This barrier was significantly associated in the
multivariate linear regression model explaining differ-
ences in ACE-I dosages (beta 0.42, p = .03). The GPs who
agreed that it is not useful to prescribe ACE-I to very old
CHF patients were prescribing lower ACE-I doses (beta
0.34, p = .04).
Self-reported barriers
The most common self-reported barrier concerned the
sharing of responsibilities with specialists (Table 1).
According to several GPs co-management with a cardiolo-
gist made it difficult to change the therapy, and some GPs
felt the cardiologist interfered too much. Furthermore,
eight GPs mentioned possible adverse effects of ACE-I as
a barrier towards prescribing. A few GPs mentioned prob-
lems with patient motivation as a barrier. Addition of the
self-reported barriers to the multivariate model did not
significantly alter any of the findings.
Analysis of patients not referred to a cardiologist
Cardiologist treatment could have confounded our analy-
sis. Patients not referred to a cardiologist in the year prior
to data collection were prescribed an ACE-I less often than
the 36% of patients that had been referred (44% versus
61% on ACE-I, t-test = -2.2, p = .03). No significant differ-
ence was found regarding ACE-I dosage. Analysis includ-
ing only the non-referred patients, however, hardly
changed our findings. Again no relationship was found
between the number of barriers and ACE-I prescribing. In
the multivariate model, there were no barriers signifi-
cantly explaining differences in the percentage of patients
currently or previously receiving an ACE-I. One additional
factor was found to be associated in the model explaining
differences in ACE-I dosages. GPs who believed that CHF
patients stable on their current medication should not be
put on an ACE-I prescribed higher dosages of ACE-I (beta
-0.48, p = .02).
Discussion
In this study we found remarkably few relationships
between perceived barriers and actual prescribing for
CHF. The problems that certain GPs acknowledged, such
as their reluctance to initiate ACE-I in already treated CHF
patients or the difficulties with gradually increasing the
ACE-I dose, were not reflected in their prescribing of these
drugs. No matter what barrier GPs report, it does not seem
to affect their management of CHF patients in general
practice.
Table 2: Number of perceived barriers and average ACE-I prescribing in CHF patients (N = number of GPs)
Number of barriers N % patients on ACE-I standardised ACE-I dose 
(mg)*
1 1 80.0 13.7
2 9 49.7 13.5
3 7 42.2 10.9
41 1 4 8 . 1 1 5 . 0
5 7 41.4 15.4
6 4 67.1 13.4
7 2 31.7 11.2
8 1 62.5 6.2
10 1 55.6 9.2
median = 4.0 (SD 1.86) 43 48.6 13.5
median internal barriers = 3.0 (SD 1.64) 41 48.5 13.5
median external barriers = 1.0 (SD 0.88) 37 47.1 12.9
* = based on a conversion using a standardised target dose of 20 mgBMC Family Practice 2005, 6:19 http://www.biomedcentral.com/1471-2296/6/19
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For some patients, GPs tried to initiate an ACE-I but treat-
ment had been stopped for various reasons. We included
these cases in our analysis, thereby focussing on all
attempts of a GP to start ACE-I treatment in CHF patients.
A third of the patients in our study were seen by a cardiol-
ogist in the year prior to data collection, which was found
to be related to receiving more ACE-I. However, subgroup
analysis including only prescriptions for patients not
recently referred to a cardiologist did not show any con-
cealed relationships.
In our study we took the overall prescribing of ACE-I for
CHF patients at GP level as primary outcome measure,
expecting to find relationships between perceived barriers
and the general prescription pattern. Since ACE-I should
be started in all CHF patients, this aggregated measure is
considered a relevant performance indicator for the CHF
treatment [17]. At patient level, however, we did observe
a lower prescription rate for patients over 85 years of age.
Therefore, we decided to look at the specific association
between the barrier for prescribing ACE-I to very old
patients and actual ACE-I prescribing in this subgroup.
Even on this specific level no significant relationship
could be found. Our findings are in line with those from
a recent explanatory study on effective management of
type 2 diabetes, where no relationship was found between
the presence of barriers perceived and the number of rec-
ommendations followed by physicians [18].
The representativity of our GP population should be con-
sidered. The 43 responding GPs were representative
regarding age and gender for the total of 97 GPs enrolled
in the larger study, and there were also no differences
regarding their prescribing of ACE-I for CHF. In compari-
son to all Dutch GPs, our study population included a rel-
atively large proportion of single-handed, male GPs that is
typical for our region. A previous study showed, however,
that such general physician and practice characteristics did
not determine ACE-I prescribing for CHF [19]. Therefore,
we do not expect that the regional selection limited the
analysis of the relationship between perceived barriers
and actual prescribing. Another matter of concern is the
power of our study to detect relevant associations. We
analysed all data on the GP level, since barriers were meas-
ured at this GP level and not linked to individual patients.
Our sample size of 43 achieved an 80% power to detect
moderate correlations of 0.41 in the univariate analyses.
In the linear regression model, this sample size achieved
an 80% power to detect an R-squared of 0.34 attributed to
11 independent variables or an R-squared of 0.26 attrib-
uted to 5 variables. This implies that there may have been
weaker associations that we have missed both in the sta-
tistical analysis and by inspecting at the univariate scatter
plots. We used medical records to measure the GPs' pre-
scribing behaviour for CHF patients. As is the case with
more than 90% of Dutch GPs, the GPs in this study pre-
scribe electronically, and these prescriptions are automat-
ically stored in the medical records. Patients were selected
as having CHF according to their GP, without independ-
ently confirming the diagnosis. This was done since our
study sought to relate perceived barriers with current man-
agement for those patients who the GP considered as
having CHF. The low percentage of diagnoses confirmed
by echocardiography reflects reality in Dutch primary care
[11,20]. The average number of 33 CHF patients identi-
fied per practice was in accordance to prevalence rates
found in other general practice registrations in The Neth-
erlands [13]. In thirteen practices, less than 10 verified
CHF patients could be identified. This was partly due to
exclusion of patients with diabetes co morbidity, and
partly due to a relatively young patient population in
these practices.
Conclusion
Interventions to improve quality of care often focus on
education and addressing perceived barriers for optimal
performance. The findings from our study imply that tar-
geting only those doctors that perceive a specific barrier
with a tailor-made programme will not be an efficient
approach. Variation in the quality of care between GPs
can not be explained by differences in the barriers they
perceive. It might even be true that being aware of a barrier
stimulates some doctors to be more active in dealing with
that barrier.
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